Digital Realty Trust Inc. (NYSE:DLR) shares fell -0.89% in last trading session and ended the day at $71.48. DLR Gross Margin is 63.60% and its has a return on assets of 2.20%. Digital Realty Trust Inc. (NYSE:DLR) quarterly performance is 17.37%.
Digital Realty Trust Inc. (NYSE:DLR) and AT&T said that, they are broadening AT&T’s colocation service offerings by expanding their alliance.
On 09 December, Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares decreased -0.15% and was closed at $6.70. INO EPS growth in last 5 year was 14.20%. Inovio Pharmaceuticals, Inc. (NASDAQ:INO) year to date (YTD) performance is -27.02%.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was upgradedby Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday, MarketBeat.com reports. The firm presently has a $7.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s price objective points to a potential upside of 11.44% from the company’s previous close.
Rite Aid Corporation (NYSE:RAD) shares remains unchanged in last trading session and ended the day at $7.95. RAD Gross Margin is 27.50% and its has a return on assets of 20.50%. Rite Aid Corporation (NYSE:RAD) quarterly performance is -6.47%.
Rite Aid Corporation (NYSE:RAD) said that it will release financial results for its Fiscal 2016 Third Quarter, which ended Nov. 28, 2015, on Thursday, Dec. 17, 2015. Given the company’s pending merger with Walgreens Boots Alliance, Inc. (Nasdaq: WBA), Rite Aid will not be holding a conference call.
Bristol-Myers Squibb Company (NYSE:BMY) caters to the Healthcare space. It has a net profit margin of 10.70% and weekly performance is 1.15%. On the last day of trading company shares ended up at $68.56. Bristol-Myers Squibb Company (NYSE:BMY) distance from 50-day simple moving average (SMA50) is 5.67%.
On 8 December, Bristol-Myers Squibb Company (NYSE:BMY) announced that it has completed the previously announced planned acquisition of Cardioxyl Pharmaceuticals, Inc. The transaction includes full rights to Cardioxyl’s lead asset CXL-1427, a novel nitroxyl (HNO) donor (prodrug) in Phase 2 clinical development as an intravenous treatment for acute decompensated heart failure (ADHF).
RadiSys Corporation (NASDAQ:RSYS) caters to the Technology space. It has a net profit margin of -9.40% and weekly performance is -3.69%. On the last day of trading company shares ended up at $2.61. RadiSys Corporation (NASDAQ:RSYS) distance from 50-day simple moving average (SMA50) is -5.38%.
Zacks cut shares of RadiSys Corporation (NASDAQ:RSYS) from a buy rating to a hold rating in a research report published on Monday morning, MarketBeat.com reports.
Leave a Reply